Mass Screening For Colorectal Cancer Research Articles

Study on Efficiency of Annual Mass Screening for Colorectal Cancer by Using Immunochemical Fecal Occulut Blood Tests

Study on Efficiency of Annual Mass Screening for Colorectal Cancer by Using Immunochemical Fecal Occulut Blood Tests

Cases with Poor Prognosis in Mass Screening For Colorectal Cancer

Cases with Poor Prognosis in Mass Screening For Colorectal Cancer

The result of mass screening for colorectal cancer in human dry dock -Toward improvement of the system for the further examination-

The result of mass screening for colorectal cancer in human dry dock -Toward improvement of the system for the further examination-

Effectiveness of the Mass Screening for Colorectal Cancer from a View-point of the Comparisons of the Coverage-rates and the Trends in Age-adjusted Death Rate between the High Coverage-rate Areas and the Control Areas

Effectiveness of the Mass Screening for Colorectal Cancer from a View-point of the Comparisons of the Coverage-rates and the Trends in Age-adjusted Death Rate between the High Coverage-rate Areas and the Control Areas

Interval Cancers in Mass Screening for Colorectal Cancer

Interval Cancers in Mass Screening for Colorectal Cancer

Detectability of Early Colorectal Cancers on Barium Enema Examination Detected by Colorectal Cancer Mass Screening

Detectability of Early Colorectal Cancers on Barium Enema Examination Detected by Colorectal Cancer Mass Screening

The study of Gastric Cancer Detected by Colorectal Cancer Mass Screening.

The study of Gastric Cancer Detected by Colorectal Cancer Mass Screening.

Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

Mass screening using the faecal occult blood test (FOBT) can reduce mortality from colorectal cancer. Reliable estimation of FOBT sensitivity is crucial in assessing the potential effectiveness of a mass-screening procedure. Available estimates could be inaccurate because they neglect the temporal aspect of screening. The aim of our study was to estimate the sensitivity of the FOBT in mass screening for colorectal cancer, taking into account the duration of the pre-clinical phase of the disease assessed by the mean sojourn time (MST), and to assess whether MST and FOBT sensitivity differ according to cancer subsite. We analysed data taken from the first round of the mass-screening programme of the department of Calvados (France), involving 164,364 subjects of whom 43.4% participated in FOB screening. MST and sensitivity were estimated using a simple empirical approach, a traditional maximum likelihood method and log-linear modelling using the Bayesian technique of Gibbs sampling. MST was estimated as between 4.5 and 5 years for all subsites combined. According to the Gibbs sampling method, MSTs were 3.5, 6.4 and 2.6 years for proximal colon, distal colon and rectal cancer, respectively. Our estimation methods give a low sensitivity for the FOBT (50%), results for different subsites being closer to each other, slightly higher for proximal cancer. Our results strongly suggest that tumour growth rates are very different according to subsite, slowest for distal cancer and speediest for rectal cancer. Consideration of FOBT sensitivity without MST appears unreliable. Our results by subsite suggest that combining FOBT and sigmoidoscopy could be a good strategy for colorectal cancer screening.

Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996.

To evaluate the influence on compliance of demographic variables and of the way of proposing a faecal occult blood test in a colorectal cancer mass screening programme. Well defined population in Burgundy (France). From 1988 to 1996 five screening rounds were conducted in people aged 45 to 74 on entering the study. The screening test was provided free of charge by primary care physicians over a four month period, then mailed to non-consultants, followed by a potential reminder letter. The whole population was invited to participate in each screening campaign. During the five successive rounds, compliance was 52.8%, 54.0%, 57.3%, 58.3%, and 56.2%. It was higher in women than in men, in those initially aged 50 to 69 than in the extreme age groups, and in urban than in rural areas. Overall, 68.7% of the invited population completed at least one screening test and 37.2% completed the five rounds. Among those who participated once in a screening campaign, between 79.6% and 87.6% participated in the succeeding ones. Compliance was higher when the test was proposed by GPs (varying between 85.2% and 94.0% according to the screening campaign) than when it was sent by post (varying between 26.0% and 33.7%). In France, a participation rate of over 50% can be achieved in colorectal cancer screening by means of a faecal occult blood test. To achieve this, primary care physicians have to play an active part in the programme and the test must be mailed to non-consultants.

Cost-effectiveness Analysis of Mass Screening for Colorectal Cancer

Cost-effectiveness Analysis of Mass Screening for Colorectal Cancer

第25回日本総合健診医学会学術大会講演抄録集 下部大腸内視鏡による大腸癌検診の評価

第25回日本総合健診医学会学術大会講演抄録集 下部大腸内視鏡による大腸癌検診の評価

第25回日本総合健診医学会学術大会講演抄録集 大腸癌検診の現状と課題

第25回日本総合健診医学会学術大会講演抄録集 大腸癌検診の現状と課題

サンオートヘモ(SAH)の大腸がん検診における臨床評価

サンオートヘモ(SAH)の大腸がん検診における臨床評価

Ccuracy of the Further examination in the mass screening for colorectal cancer

ccuracy of the Further examination in the mass screening for colorectal cancer

第24回日本総合健診医学会学術大会講演抄録集 免疫便潜血検査による大腸癌検診の現状と課題

第24回日本総合健診医学会学術大会講演抄録集 免疫便潜血検査による大腸癌検診の現状と課題

Mass screening for colorectal cancer by a local medical association

Mass screening for colorectal cancer by a local medical association

第24回日本総合健診医学会学術大会講演抄録集 大腸内視鏡による大腸癌検診の評価

第24回日本総合健診医学会学術大会講演抄録集 大腸内視鏡による大腸癌検診の評価

Mass screening for colorectal cancer at an occupational group, the second report

Mass screening for colorectal cancer at an occupational group, the second report

An Evaluation on Mass Screening for Colorectal Cancer with Further Examination

An Evaluation on Mass Screening for Colorectal Cancer with Further Examination

COLORECTAL CANCER SCREENING

The decision whether to launch a screening program in asymptomatic patients of average risk for colorectal cancer and the selection of the appropriate protocol for screening are complex issues. There are still many unanswered questions. Many organizations such as the American Cancer Society, the World Health Organization Collaborating Center for the Prevention of Colorectal Cancer, and the U.S. National Cancer Institute advocate screening with annual Hemoccult tests and screening with flexible sigmoidoscopy every 3 to 5 years in patients more than 50 years of age. The U.S. Preventive Services Task Force, the Canadian Task Force on Periodic Health Examination, and the International Union Against Cancer have not recommended screening asymptomatic average-risk patients for colorectal cancer. One study showed a small but significant benefit (3 per 1000) of the rehydrated annual Hemoccult test in reducing mortality from colorectal cancer. To embark on a mass screening strategy as recommended, however, would require significant costs, increases in physician training, improved access to the requisite technology, and enhancements in patient and physician compliance. Furthermore, the high false-positive rates of the rehydrated Hemoccult tests would lead to many unnecessary tests, causing greater expense as well as patient discomfort and anxiety. It is, therefore, premature to recommend mass screening for colorectal cancer in asymptomatic individuals at this time. Further research is needed to identify risk factors (such as genetic markers) better and to develop and evaluate screening strategies targeted at those with high risk for colorectal cancer. In the meantime, efforts at primary prevention for the general population should be increased (through nutrition and exercise). Patients over the age of 50 who desire screening should be given information of the benefits and risks of screening and together with their physicians decide on a screening strategy that suits their needs and values.